Profile data is unavailable for this security.
About the company
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
- Revenue in SEK (TTM)191.89m
- Net income in SEK-340.89m
- Incorporated2008
- Employees71.00
- LocationXbrane Biopharma ABRetzius Vag 8SOLNA 171 65SwedenSWE
- Phone+46 855905600
- Websitehttps://xbrane.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kancera AB | 0.00 | -53.07m | 236.07m | 5.00 | -- | 2.84 | -- | -- | -0.5955 | -0.5955 | 0.00 | 0.6849 | 0.00 | -- | -- | 0.00 | -56.73 | -54.82 | -66.40 | -66.21 | -- | 96.28 | -- | -7,249.06 | -- | -- | 0.00 | -- | -- | -- | -23.64 | -- | -- | -- |
Abliva AB | 137.00k | -102.13m | 245.97m | 6.00 | -- | 2.39 | -- | 1,795.43 | -0.0928 | -0.0928 | 0.0001 | 0.0638 | 0.0013 | -- | 0.0062 | -- | -93.81 | -74.59 | -103.87 | -86.98 | -35,826.28 | -- | -74,542.34 | -65,958.89 | -- | -- | 0.00 | -- | 341.94 | 93.89 | -12.02 | -- | -19.74 | -- |
Intervacc AB | 9.78m | -102.66m | 249.93m | 15.00 | -- | 1.23 | -- | 25.56 | -1.36 | -1.36 | 0.1291 | 2.68 | 0.0355 | 3.19 | 1.62 | 651,933.30 | -37.23 | -17.62 | -40.38 | -18.77 | -551.10 | -243.59 | -1,049.76 | -626.90 | 2.90 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
Xintela AB | 381.00k | -40.83m | 260.49m | -- | -- | -- | -- | 683.71 | -0.0817 | -0.0817 | 0.0008 | -0.0319 | 0.0306 | -- | 0.0493 | -- | -327.65 | -181.06 | -- | -391.61 | 100.00 | -- | -10,717.06 | -235,894.00 | -- | -203.91 | -- | -- | -- | -45.54 | 18.32 | -- | -61.47 | -- |
Annexin Pharmaceuticals AB (publ) | 0.00 | -52.36m | 285.68m | 4.00 | -- | 7.93 | -- | -- | -0.1873 | -0.1873 | 0.00 | 0.0676 | 0.00 | -- | -- | 0.00 | -162.59 | -125.42 | -220.41 | -151.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.17 | -- | -- | -- |
Lifecare ASA | 15.53m | -49.99m | 292.83m | 32.00 | -- | 31.96 | -- | 18.85 | -0.3152 | -0.3152 | 0.0999 | 0.632 | 0.1564 | -- | -- | 502,995.00 | -50.29 | -40.00 | -56.16 | -45.26 | -- | -- | -321.48 | -175.53 | -- | -- | 0.0918 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
Lytix Biopharma AS | -96.50bn | -96.50bn | 295.87m | 10.00 | -- | 5.18 | -- | -- | -- | -- | -- | 1.19 | -- | -- | -- | -- | -- | -56.91 | -- | -65.83 | -- | -- | -- | -771.78 | -- | -- | 0.0482 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
Alzinova AB | 300.00k | -18.12m | 299.60m | 5.00 | -- | 1.78 | -- | 998.65 | -0.332 | -0.332 | 0.0055 | 1.89 | 0.0025 | -- | 0.4752 | 60,000.00 | -15.15 | -10.77 | -15.91 | -11.27 | -2,621.00 | -- | -6,039.67 | -18,447.90 | -- | -392.89 | 0.0076 | -- | -- | -- | -25.92 | -- | 15.81 | -- |
Guard Therapeutics Intrntnl AB (publ) | 0.00 | -78.82m | 314.75m | 6.00 | -- | 3.97 | -- | -- | -7.83 | -7.83 | 0.00 | 6.45 | 0.00 | -- | -- | -- | -70.61 | -69.56 | -86.38 | -78.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.4289 | -- | -- | -- |
Xbrane Biopharma AB | 191.89m | -340.89m | 320.43m | 71.00 | -- | 1.05 | -- | 1.67 | -1.01 | -1.26 | 0.3403 | 0.1991 | 0.209 | 0.7028 | 24.13 | 2,063,301.00 | -37.14 | -40.98 | -66.96 | -67.24 | 43.32 | -- | -177.65 | -364.40 | 1.07 | -20.51 | 0.357 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
Medivir AB | 6.83m | -105.92m | 327.53m | 10.00 | -- | 1.86 | -- | 47.93 | -1.45 | -1.45 | 0.0824 | 1.57 | 0.0311 | -- | 1.12 | 683,300.00 | -48.26 | -28.91 | -61.14 | -34.77 | -1,152.23 | -467.42 | -1,550.15 | -675.96 | -- | -- | 0.0543 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
Herantis Pharma Oyj | 0.00 | -6.97m | 330.35m | 10.00 | -- | 14.23 | 13.99 | -- | -0.0146 | -0.0146 | 0.00 | 0.1012 | 0.00 | -- | -- | 0.00 | -13.93 | -80.46 | -27.32 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0145 | -- | -- | -- | 103.00 | -- | -- | -- |
Thor Medical ASA | 0.00 | -17.91m | 358.10m | 1.00 | -- | 1.43 | -- | -- | -0.0873 | 0.021 | 0.00 | 1.11 | 0.00 | -- | -- | 0.00 | -9.82 | -79.17 | -10.54 | -113.94 | -- | -- | -- | -- | -- | -- | 0.0035 | -- | -- | -- | -- | -- | -- | -- |
SynAct Pharma AB | 0.00 | -165.96m | 362.17m | 5.00 | -- | 1.94 | -- | -- | -4.75 | -4.75 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -61.52 | -125.17 | -67.60 | -151.70 | -- | -- | -- | -- | -- | -231.85 | 0.0076 | -- | -- | -- | -117.54 | -- | -- | -- |
Curasight A/S | -43.37m | -48.45m | 370.35m | 4.00 | -- | 19.14 | -- | -- | -1.51 | -1.51 | -1.35 | 0.6008 | -0.7563 | -- | -- | -7,107,500.00 | -84.49 | -24.61 | -111.31 | -26.01 | -- | -- | -- | -- | -- | -32.26 | 0.4439 | -- | -123.97 | -- | -42.62 | -- | -- | -- |
Initiator Pharma A/S | 0.00 | -25.80m | 382.08m | 3.00 | -- | 14.03 | -- | -- | -0.4702 | -0.4702 | 0.00 | 0.5145 | 0.00 | -- | -- | 0.00 | -65.39 | -68.27 | -73.28 | -74.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
Data as of Oct 10 2024. Currency figures normalised to Xbrane Biopharma AB's reporting currency: Swedish Krona SEK
Holder | Shares | % Held |
---|---|---|
Handelsbanken Fonder ABas of 31 Jul 2024 | 51.94m | 3.42% |
Swedbank Robur Fonder ABas of 29 May 2024 | 15.20m | 1.00% |
Teknik Innovation Norden Fonder ABas of 31 Dec 2022 | 13.70m | 0.90% |
SEB Investment Management ABas of 28 Jun 2024 | 7.60m | 0.50% |
Storebrand Asset Management ASas of 30 Jun 2024 | 1.83m | 0.12% |
Skandia Investment Management ABas of 31 May 2024 | 1.13m | 0.07% |
FCG Fonder ABas of 31 Dec 2023 | 659.32k | 0.04% |
SSgA Funds Management, Inc.as of 03 Jul 2024 | 103.60k | 0.01% |
WBS H�nicke Verm�gensverwaltung GmbHas of 31 Mar 2024 | 85.00k | 0.01% |
Danske Bank A/S (Investment Management)as of 31 Jul 2024 | 66.66k | 0.00% |
More ▼
Data from 31 Dec 2022 - 31 Jul 2024Source: FactSet Research Systems Inc.